Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 2

Sponsor Class

OTHER 12NIH 2INDUSTRY 2NETWORK 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Esophageal Neoplasms 1Cardiovascular Diseases 1Carcinoma, Squamous Cell 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Raloxifene Hydrochloride × Clear all
NCT01077817 2022-02-03

Observational Study of Incidence Rates of Esophageal Cancer in Women Taking Medications for the Prevention or Treatment of Osteoporosis (MK-0217A-352)

Organon and Co

Completed
684,815 enrolled 6 charts
Gastrointestinal

Adenocarcinoma, Carcinoma, Squamous Cell, Esophageal Neoplasms

NCT00190593 2007-01-26

Raloxifene Use for The Heart

Eli Lilly and Company

Phase 3 Completed
10,000 enrolled
Breast

Breast Neoplasms, Cardiovascular Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡